Literature DB >> 17022621

Nanotools for megaproblems: probing protein misfolding diseases using nanomedicine modus operandi.

Vladimir N Uversky1, Alexander V Kabanov, Yuri L Lyubchenko.   

Abstract

Misfolding and self-assembly of proteins in nanoaggregates of different sizes and morphologies (nanoensembles, primary nanofilaments, nanorings, filaments, protofibrils, fibrils, etc.) is a common theme unifying a number of human pathologies termed protein misfolding diseases. Recent studies highlight increasing recognition of the public health importance of protein misfolding diseases, including various neurodegenerative disorders and amyloidoses. It is understood now that the first essential elements in the vast majority of neurodegenerative processes are misfolded and aggregated proteins. Altogether, the accumulation of abnormal protein nanoensembles exerts toxicity by disrupting intracellular transport, overwhelming protein degradation pathways, and/or disturbing vital cell functions. In addition, the formation of inclusion bodies is known to represent a major problem in the production of recombinant therapeutic proteins. Formulation of these therapeutic proteins into delivery systems and their in vivo delivery are often complicated by protein association. Thus, protein folding abnormalities and subsequent events underlie a multitude of human pathologies and difficulties with protein therapeutic applications. The field of medicine therefore can be greatly advanced by establishing a fundamental understanding of key factors leading to misfolding and self-assembly responsible for various protein folding pathologies. This article overviews protein misfolding diseases and outlines some novel and advanced nanotechnologies, including nanoimaging techniques, nanotoolboxes and nanocontainers, complemented by appropriate ensemble techniques, all focused on the ultimate goal to establish etiology and to diagnose, prevent, and cure these devastating disorders.

Entities:  

Mesh:

Year:  2006        PMID: 17022621      PMCID: PMC1880889          DOI: 10.1021/pr0603349

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  195 in total

Review 1.  Neuroprotective peptide drug delivery and development: potential new therapeutics.

Authors:  I Gozes
Journal:  Trends Neurosci       Date:  2001-12       Impact factor: 13.837

Review 2.  Protein degradation and protection against misfolded or damaged proteins.

Authors:  Alfred L Goldberg
Journal:  Nature       Date:  2003-12-18       Impact factor: 49.962

3.  A general model for amyloid fibril assembly based on morphological studies using atomic force microscopy.

Authors:  Ritu Khurana; Cristian Ionescu-Zanetti; Maighdlin Pope; Jie Li; Liza Nielson; Marina Ramírez-Alvarado; Lynn Regan; Anthony L Fink; Sue A Carter
Journal:  Biophys J       Date:  2003-08       Impact factor: 4.033

4.  Amyloid beta protein forms ion channels: implications for Alzheimer's disease pathophysiology.

Authors:  H Lin; R Bhatia; R Lal
Journal:  FASEB J       Date:  2001-11       Impact factor: 5.191

Review 5.  Bioencapsulation within synthetic polymers (Part 1): sol-gel encapsulated biologicals.

Authors:  I Gill; A Ballesteros
Journal:  Trends Biotechnol       Date:  2000-07       Impact factor: 19.536

6.  Amyloid fibril formation by A beta 16-22, a seven-residue fragment of the Alzheimer's beta-amyloid peptide, and structural characterization by solid state NMR.

Authors:  J J Balbach; Y Ishii; O N Antzutkin; R D Leapman; N W Rizzo; F Dyda; J Reed; R Tycko
Journal:  Biochemistry       Date:  2000-11-14       Impact factor: 3.162

Review 7.  Prion diseases of humans and animals: their causes and molecular basis.

Authors:  J Collinge
Journal:  Annu Rev Neurosci       Date:  2001       Impact factor: 12.449

8.  Protein-only transmission of three yeast prion strains.

Authors:  Chih-Yen King; Ruben Diaz-Avalos
Journal:  Nature       Date:  2004-03-18       Impact factor: 49.962

9.  High-resolution electron microscopic analysis of the amyloid fibril.

Authors:  T Shirahama; A S Cohen
Journal:  J Cell Biol       Date:  1967-06       Impact factor: 10.539

10.  Reconstitution of amyloid fibrils from alkaline extracts.

Authors:  T Shirahama; A S Cohen
Journal:  J Cell Biol       Date:  1967-11       Impact factor: 10.539

View more
  7 in total

1.  Protein folding: are we there yet?

Authors:  A Clay Clark
Journal:  Arch Biochem Biophys       Date:  2008-01-01       Impact factor: 4.013

2.  Early stages for Parkinson's development: alpha-synuclein misfolding and aggregation.

Authors:  Junping Yu; Yuri L Lyubchenko
Journal:  J Neuroimmune Pharmacol       Date:  2008-07-17       Impact factor: 4.147

3.  HIV-1 protein-mediated amyloidogenesis in rat hippocampal cell cultures.

Authors:  M Y Aksenov; M V Aksenova; C F Mactutus; R M Booze
Journal:  Neurosci Lett       Date:  2010-04-02       Impact factor: 3.046

4.  Effect of electrostatics on aggregation of prion protein Sup35 peptide.

Authors:  Alexander M Portillo; Alexey V Krasnoslobodtsev; Yuri L Lyubchenko
Journal:  J Phys Condens Matter       Date:  2012-03-30       Impact factor: 2.333

5.  AFM for analysis of structure and dynamics of DNA and protein-DNA complexes.

Authors:  Yuri L Lyubchenko; Luda S Shlyakhtenko
Journal:  Methods       Date:  2008-10-07       Impact factor: 3.608

Review 6.  Multidrug resistance: Physiological principles and nanomedical solutions.

Authors:  Sijumon Kunjachan; Błażej Rychlik; Gert Storm; Fabian Kiessling; Twan Lammers
Journal:  Adv Drug Deliv Rev       Date:  2013-10-10       Impact factor: 15.470

7.  New technology and clinical applications of nanomedicine: highlights of the second annual meeting of the American Academy of Nanomedicine (Part I).

Authors:  Chiming Wei; Yuri L Lyubchenko; Hamid Ghandehari; Justin Hanes; Kathleen J Stebe; Hai-Quan Mao; Donald T Haynie; Donald A Tomalia; Marianna Foldvari; Nancy Monteiro-Riviere; Petia Simeonova; Shuming Nie; Hidezo Mori; Susan P Gilbert; David Needham
Journal:  Nanomedicine       Date:  2006-12       Impact factor: 5.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.